secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001437749-23-031420
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa Q3 2023: cash $94M; two Phase 2 trials 80% enrolled; net loss details
----------------------------------------------------------------------------

- Cash and cash equivalents $94.0M as of Sept 30, 2023.
- Two Phase 2 trials (Karisma-Endoxifen, I-SPY 2) at 80% enrollment; data expected H2 2024.
- R&D expense $4.5M in Q3 2023, down 13% YoY; G&A $3.0M, flat YoY.
- Interest income $1.3M in Q3 2023 vs $0.2M in Q3 2022 due to higher rates and balance.
- Jonathan Finn appointed to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000143774923031420/0001437749-23-031420-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000143774923031420/atos20231106c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-031420

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer